Detalles de la búsqueda
1.
The Role of SGLT2 Inhibitor Ipragliflozin on Cardiac Hypertrophy and microRNA Expression Profiles in a Non-diabetic Rat Model of Cardiomyopathy.
Biol Pharm Bull
; 45(9): 1321-1331, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36047201
2.
Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
Endocr Res
; 45(2): 147-161, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31955626
3.
Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
Biol Pharm Bull
; 42(10): 1707-1712, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31582658
4.
In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
Biol Pharm Bull
; 42(3): 507-511, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30828082
5.
First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats.
Clin Exp Pharmacol Physiol
; 46(3): 266-273, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30485488
6.
Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice.
Biol Pharm Bull
; 41(5): 761-769, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29709913
7.
The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Biol Pharm Bull
; 40(5): 675-680, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28458353
8.
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
J Pharmacol Sci
; 131(3): 198-208, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27430987
9.
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
J Pharmacol Sci
; 130(3): 159-69, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26970780
10.
Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
Clin Exp Pharmacol Physiol
; 42(1): 87-93, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25311502
11.
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
J Pharmacol Sci
; 120(1): 36-44, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22971845
12.
Synthesis and evaluation of N-phenyl-(2-aminothiazol-4-yl)acetamides with phenoxypropanolamine moiety as selective ß3-adrenergic receptor agonists.
Chem Pharm Bull (Tokyo)
; 60(5): 647-58, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22689403
13.
Synthesis and evaluation of novel phenylethanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists.
Chem Pharm Bull (Tokyo)
; 58(4): 533-45, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20410638
14.
Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
Bioorg Med Chem
; 17(15): 5510-9, 2009 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19581100
15.
Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists.
Bioorg Med Chem
; 17(9): 3283-94, 2009 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19362005
16.
SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Physiol Rep
; 7(22): e14286, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31782258
17.
Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy.
Life Sci
; 230: 19-27, 2019 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31125563
18.
Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
Naunyn Schmiedebergs Arch Pharmacol
; 377(3): 209-17, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18398600
19.
Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.
Life Sci
; 197: 80-90, 2018 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29425766
20.
Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Naunyn Schmiedebergs Arch Pharmacol
; 391(4): 395-406, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29374293